Posted inBiotechnology
Insilico agrees on $66M deal to split rights for preclinical NLRP3 inhibitor with new Chinese biotech
Artificial-intelligence-powered drug developer Insilico Medicine is set for a $10 million upfront payment from a fresh-faced Chinese biotech for half…








